New bone graft shows promise for mending tough leg breaks
NCT ID NCT04960722
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a new bone graft material (OIF/β-TCP) in 35 people with severe open fractures of the shin bone (tibia). The goal was to see if it helps bones heal when they are slow to mend. Participants were followed for up to 52 weeks after the graft was implanted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OIF/β-TCP (BiG001) bone graft
What this could lead to
If successful, this could offer a new option to help heal severe leg fractures that are slow to mend.
What could go wrong
This is a small, early study with only 35 participants. The results may not apply to everyone, and there is always a risk the graft may not work or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TIBIA FRACTURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BioGend Therapeutics
Taipei, Taiwan